唾液腺恶性多形性腺瘤HER2基因扩增与临床病理特征及预后的关系

doi:10.19438/j.cjoms.2018.01.003

中国口腔颌面外科杂志 ›› 2018, Vol. 16 ›› Issue (1): 12-19.doi: 10.19438/j.cjoms.2018.01.003

唾液腺恶性多形性腺瘤HER2基因扩增与临床病理特征及预后的关系

夏亮^1,2,*, 汪洋^1,*, 胡宇华¹, 顾挺¹, 李江¹, 石慧敏^3#, 田臻^1#

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔病理科,2.口腔颅颌面科, 上海市口腔医学重点实验室,上海市口腔医学研究所,国家口腔疾病临床研究中心,上海 200011;
3.上海交通大学医学院附属第九人民医院放射科,上海 200011

收稿日期:2017-04-10 修回日期:2017-06-13 出版日期:2018-01-20 发布日期:2018-02-11
通讯作者: 田臻,E-mail：tian0304_cn@163.com;石慧敏,E-mail:2240542827@qq.com。^#共同通信作者
作者简介:夏亮（1990-）,男,硕士,E-mail：anglexialiang@126.com;汪洋（1989-）,男,硕士,E-mail：cmfuyangwang@126.com。<sup>*</sup>并列第一作者
基金资助:
国家自然科学基金（81272976,81372910）

Relationship of HER2 gene amplification to clinicopathological characteristics and prognosis of salivary gland malignant pleomorphic adenoma

XIA Liang^1,2, WANG Yang¹, HU Yu-hua¹, GU Ting¹, LI Jiang¹, SHI Hui-min³, TIAN Zhen¹

1.Department of Oral Pathology, 2.Department of Oral and Cranio-maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology; National Clinical Research Center of Stomatology. Shanghai 200011;
3.Department of Radiology, Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine.Shanghai 200011, China

Received:2017-04-10 Revised:2017-06-13 Online:2018-01-20 Published:2018-02-11

摘要/Abstract

摘要： 目的: 检测唾液腺恶性多形性腺瘤（malignant pleomorphic adenoma,MPA）中人上皮生长因子受体2（human epithelial growth factor receptor 2,HER2）蛋白表达、基因扩增情况,分析其与肿瘤临床病理及患者预后的相关性,以期评估其作为靶向治疗位点的可能性。方法: 应用免疫组织化学染色法检测140例MPA患者肿瘤组织中HER2蛋白的表达,对HER2基因扩增情况不明确者（HER2 2+）行荧光原位杂交,确定基因扩增状态。统计140例患者临床病理资料并进行随访,应用SPSS16.0软件包中的Kaplan-Meier、Cox比例风险模型,分析HER2基因扩增与MPA肿瘤临床病理及患者预后的相关性。结果: 140例MPA患者中,HER2阳性率为25%。腺癌亚型MPA中,HER2阳性率达到40.5%（32/79）,显著高于肌上皮癌亚型MPA（4.9%,3/61）（P<0.05）。HER2阳性与肿瘤患者性别、组织学分级及N分期显著相关。生存分析显示,HER2阳性患者总生存率及疾病别生存率低。结论: HER2基因过表达及扩增与MPA肿瘤细胞恶变亚型显著相关,并且提示MPA患者较差的预后状态。

关键词: HER2, 恶性多形性腺瘤, 组织分化, 靶向治疗

Abstract: PURPOSE: To investigate HER2 gene overexpression or amplification in human salivary malignant pleomorphic adenoma (MPA), and analyze the association between HER2 and tumor clinicopathological characteristics, as well as prognosis, in order to assess its potential as a therapeutic target. METHODS: The expression of HER2 protein was detected by immunohistochemistry in 140 patients with MPA, and the amplification of HER2 gene was determined by fluorescence in situ hybridization for HER2 2+ cases. The clinicopathological data of 140 patients were reviewed. The correlation between HER2 gene amplification and clinicopathological features and prognosis of MPA patients was analyzed using SPSS 16.0 software package. RESULTS: The positive rate of HER2 in 140 patients with MPA was 25%. The positive rate of HER2 in adenocarcinoma subtype of MPA was 40.5% (32/79), which was significantly higher than that of myoepithelial carcinoma subtype MPA (4.9%, 3/61, P<0.05). HER2 positive staining was significantly correlated with gender, histological grade and N stage. Survival analysis showed that overall survival and disease-specific survival were lower in HER2 positive patients. CONCLUSION: Overexpression and amplification of HER2 gene is significantly correlated with the malignant subtype of MPA tumor cells, and suggests a poor prognosis in patients with MPA.

Key words: HER2, Malignant pleomorphic tumor, Differentiation, Target therapy

中图分类号:

R739.8

夏亮, 汪洋, 胡宇华, 顾挺, 李江, 石慧敏, 田臻. 唾液腺恶性多形性腺瘤HER2基因扩增与临床病理特征及预后的关系[J]. 中国口腔颌面外科杂志, 2018, 16(1): 12-19.

XIA Liang, WANG Yang, HU Yu-hua, GU Ting, LI Jiang, SHI Hui-min, TIAN Zhen. Relationship of HER2 gene amplification to clinicopathological characteristics and prognosis of salivary gland malignant pleomorphic adenoma[J]. China J Oral Maxillofac Surg, 2018, 16(1): 12-19.

参考文献

[1] Hashimoto K, Yamamoto H, Shiratsuchi H, et al.HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study[J]. Histopathology, 2012, 60(6B): E131-142.
[2] Tian Z, Li L, Wang L, et al.Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 235-242.
[3] Altemani A, Martins MT, Freitas L, et al.Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression[J]. Histopathology, 2005, 46(6): 635-641.
[4] Guzzo M, Locati LD, Prott FJ, et al.Major and minor salivary gland tumors[J]. Crit Rev Oncol Hematol, 2010, 74(2): 134-148.
[5] Hirsch FR, Varella-Garcia M, Franklin WA, et al.Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas[J]. Brit J Cancer, 2002, 86(9): 1449-1456.
[6] Marx AH, Tharun L, Muth J, et al.HER-2 amplification is highly homogenous in gastric cancer[J]. Hum Pathol, 2009, 40(6): 769-777.
[7] Glisson B, Colevas AD, Haddad R, et al.HER2 expression in salivary gland carcinomas: dependence on histological subtype[J]. Clin Cancer Res, 2004, 10(3): 944-946.
[8] Yan M, Parker BA, Schwab R, et al.HER2 aberrations in cancer: implications for therapy[J]. Cancer Treat Rev, 2014, 40(6): 770-780.
[9] Figueroa-Magalhaes MC, Jelovac D, Connolly RM, et al.Treatment of HER2-positive breast cancer[J]. Breast, 2014, 23(2): 128-136.
[10] Clauditz TS, Reiff M, Gravert L, et al.Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas[J]. Pathology, 2011, 43(5): 459-464.
[11] Williams MD, Roberts DB, Kies MS, et al.Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance[J]. Clin Cancer Res, 2010, 16(8): 2266-2274.
[12] Limaye SA, Posner MR, Krane JF, et al.Trastuzumab for the treatment of salivary duct carcinoma[J]. Oncologist, 2013, 18(3): 294-300.
[13] Lewis JE, Olsen KD, Sebo TJ.Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases[J]. Hum Pathol, 2001, 32(6): 596-604.
[14] Di Palma S, Skálová A, Vanìèek T, et al.Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry[J]. Histopathology, 2005, 46(2): 144-152.
[15] Freitas LL, Araujo VC, Martins MT, et al.Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation[J]. Int J Surg Pathol, 2005, 13(4): 337-342.
[16] Nishijima T, Yamamoto H, Nakano T, et al.Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma[J]. Hum Pathol, 2015, 46(11): 1730-1743.
[17] Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
[18] Kadowaki S, Yatabe Y, Hirakawa H, et al.Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma[J]. Case Rep Oncol, 2013, 6(3): 450-455.
[19] Sharon E, Kelly RJ, Szabo E.Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine[J]. Head Neck Oncol, 2010, 2: 12.
[20] Slamon DJ, Clark GM, Wong SG, et al.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182.
[21] Lee JS, Kwon OJ, Park JJ, et al.Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?[J]. J Oral Maxillofac Surg, 2014, 72(5): 1023-1031.

唾液腺恶性多形性腺瘤HER2基因扩增与临床病理特征及预后的关系

Relationship of HER2 gene amplification to clinicopathological characteristics and prognosis of salivary gland malignant pleomorphic adenoma

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	吴亚平, 高嘉敏, 孙树洋. HPV相关口咽癌诊疗进展[J]. 中国口腔颌面外科杂志, 2022, 20(6): 599-606.
[2]	游元和, 田卓炜, 杜仲, 肖孟, 许贵松, 郑家伟, 王延安. 靶向YAP协同强化selumetinib抑制神经纤维瘤相关施万细胞生长的体外研究[J]. 中国口腔颌面外科杂志, 2022, 20(4): 347-353.
[3]	陈澜, 张志愿, 孙树洋. 从“合成致死”策略的视角浅谈头颈鳞癌靶向治疗[J]. 中国口腔颌面外科杂志, 2021, 19(3): 278-283.
[4]	夏亮, 汪洋, 胡宇华, 王丽珍, 顾挺, 李江, 田臻. HER2基因在唾液腺恶性多形性腺瘤细胞增殖、周期、凋亡中的作用[J]. 中国口腔颌面外科杂志, 2018, 16(4): 310-316.
[5]	夏亮, 胡宇华, 王丽珍, 顾挺, 李江, 田臻. 唾液腺恶性多形性腺瘤中CDH1基因启动子甲基化与E-cadherin表达的相关性分析[J]. 中国口腔颌面外科杂志, 2018, 16(2): 120-125.
[6]	夏亮, 张春叶, 胡宇华, 钱佳骏, 李江, 田臻. 启动子甲基化状况对唾液腺恶性多形性腺瘤体外细胞系细胞E-cadherin表达的影响[J]. 中国口腔颌面外科杂志, 2016, 14(4): 308-314.
[7]	郭伟;任国欣;李朝军;吴云腾;张陈平;孙坚;张志愿;邱蔚六. 晚期口腔颌面-头颈鳞癌EGFR单抗靶向治疗—71例临床分析 [J]. 中国口腔颌面外科杂志, 2013, 11(2): 128-130.